Inhibition of red cell membrane lipid peroxidation by sulphasalazine and 5-aminosalicylic acid
- PMID: 1683330
- PMCID: PMC1379377
- DOI: 10.1136/gut.32.10.1156
Inhibition of red cell membrane lipid peroxidation by sulphasalazine and 5-aminosalicylic acid
Abstract
The effects of sulphasalazine, 5-aminosalicylic acid (5-ASA), and sulphapyridine on peroxidation of red cell membrane lipids, measured as malondialdehyde production, were assessed. Sulphasalazine and 5-ASA, at concentrations of 10(-5)-10(-3) M significantly inhibit lipid peroxidation, suggesting an antioxidant action that may explain the efficacy of these drugs in treating inflammatory bowel disease. Sulphapyridine, which is not effective in inflammatory bowel disease inhibited malondialdehyde production at a concentration of 10(-3) M only.
Similar articles
-
The effects of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid on lipid peroxidation in erythrocytes and prostaglandin production by mononuclear cells.Aliment Pharmacol Ther. 1992 Dec;6(6):671-83. doi: 10.1111/j.1365-2036.1992.tb00731.x. Aliment Pharmacol Ther. 1992. PMID: 1486154
-
The effects of sulphasalazine and its metabolites on prostaglandin production by human mononuclear cells.Biochem Pharmacol. 1992 Jun 9;43(11):2369-76. doi: 10.1016/0006-2952(92)90315-a. Biochem Pharmacol. 1992. PMID: 1351726
-
Sulphasalazine, sulphapyridine or 5-aminosalicylic acid--which is the active moiety in rheumatoid arthritis?Br J Rheumatol. 1995 Nov;34 Suppl 2:16-9. Br J Rheumatol. 1995. PMID: 8535642 Review.
-
Inhibition of intestinal macrophage chemotaxis to leukotriene B4 by sulphasalazine, olsalazine, and 5-aminosalicylic acid.Aliment Pharmacol Ther. 1988 Jun;2(3):203-11. doi: 10.1111/j.1365-2036.1988.tb00689.x. Aliment Pharmacol Ther. 1988. PMID: 2908754
-
Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.Clin Pharmacokinet. 1985 Jul-Aug;10(4):285-302. doi: 10.2165/00003088-198510040-00001. Clin Pharmacokinet. 1985. PMID: 2864155 Review.
Cited by
-
Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.Drugs. 2000 Apr;59(4):929-56. doi: 10.2165/00003495-200059040-00016. Drugs. 2000. PMID: 10804042 Review.
-
Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications.Int J Mol Sci. 2019 Oct 9;20(20):4996. doi: 10.3390/ijms20204996. Int J Mol Sci. 2019. PMID: 31601031 Free PMC article. Review.
-
Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.Drugs. 1999 Mar;57(3):383-408. doi: 10.2165/00003495-199957030-00013. Drugs. 1999. PMID: 10193690 Review.
-
Resistance of erythrocytes to lipid peroxidation in alcoholic patients.Gut. 1994 Dec;35(12):1753-6. doi: 10.1136/gut.35.12.1753. Gut. 1994. PMID: 7829014 Free PMC article.
-
Increases in free radicals and cytoskeletal protein oxidation and nitration in the colon of patients with inflammatory bowel disease.Gut. 2003 May;52(5):720-8. doi: 10.1136/gut.52.5.720. Gut. 2003. PMID: 12692059 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources